Home › Companies › ATEA PHARMACEUTICALS INC. › 2024-2025

ATEA PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and ATEA PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.

5Ballot items
119Asset managers
777Fund votes
June 20, 2025Meeting date

Results at a glance

Meeting of June 20, 2025: 5 items on ATEA PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2025: 5 without a stated outcome.

Material dissent

Elect Director: Bruno Lucidi 79% of votes cast Outcome not stated Director under 80%
Elect Director: Polly Murphy, DVM, PhD 70% of votes cast Outcome not stated Director under 80%
Elect Director: Bruce Polsky, MD, MACP, FIDSA 79% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ATEA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ATEA PHARMACEUTICALS INC.

These tallies are ATEA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ATEA PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 20, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Bruno Lucidi	46,640,587	--	--	12,559,084	15,781,736	79%	Not verified	—
Elect Director: Polly Murphy, DVM, PhD	41,184,263	--	--	18,015,408	15,781,736	70%	Not verified	—
Elect Director: Bruce Polsky, MD, MACP, FIDSA	46,597,653	--	--	12,602,018	15,781,736	79%	Not verified	—
2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025	73,766,274	1,192,659	22,474	--	0	98%	Not verified	—
3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers	46,450,302	12,107,029	642,340	--	15,781,736	79%	Not verified	—

Source: ATEA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 20, 2025 — read the filing on EDGAR.

How asset managers voted at the ATEA PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 119 asset managers that disclosed a ATEA PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Bruce Polsky, MD, MACP, FIDSA

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD

FOR: 46,597,653WITHHELD: 12,602,018

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of Class II Directors: Bruce Polsky, MD, MACP, FIDSA

ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bruce Polsky, MD, MACP, FIDSA”): 46,597,653 for, 12,602,018 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 15,155,741 for, 137,333 withheld, 11,984 abstained.

FOR

FOR: 15,155,741ABSTAIN: 11,984WITHHOLD: 137,333

Largest asset managers voting on “Election of Class II Directors: Bruce Polsky, MD, MACP, FIDSA” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Withheld	Vote
Vanguard	4,765,568	0	For
Fidelity	3,982,987	0	For
BlackRock	3,647,018	0	For
Charles Schwab	621,155	0	For
JPMorgan	288,714	0	For
Equitable	138,793	119,220	Mixed
TIAA	254,249	0	For
American Century	163,093	0	For
BRIDGEWAY FUNDS INC	133,300	0	For
QUANTITATIVE MASTER SERIES LLC	132,546	0	For
Goldman Sachs	131,537	0	For
AIG/SunAmerica	90,747	0	For
Lincoln Financial	78,650	4,025	For
Brighthouse	70,784	0	For
MASTER INVESTMENT PORTFOLIO	70,325	0	For
Delaware/Macquarie	70,000	0	For
Nationwide	64,479	0	For
T. Rowe Price	50,656	0	For
Global X	46,292	0	For
Voya	44,486	0	For
Northern Trust	40,817	0	For
Pacific Life	39,227	0	For
Bridge Builder Trust	36,183	0	For
Invesco	34,510	0	For
Columbia Threadneedle	33,201	0	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

2. Elect Director: Bruno Lucidi

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD

FOR: 46,640,587WITHHELD: 12,559,084

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of Class II Directors: Bruno Lucidi

ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bruno Lucidi”): 46,640,587 for, 12,559,084 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 42 asset managers below reported 15,155,741 for, 137,333 withheld, 11,984 abstained.

FOR

FOR: 15,155,741ABSTAIN: 11,984WITHHOLD: 137,333

Largest asset managers voting on “Election of Class II Directors: Bruno Lucidi” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Withheld	Vote
Vanguard	4,765,568	0	For
Fidelity	3,982,987	0	For
BlackRock	3,647,018	0	For
Charles Schwab	621,155	0	For
JPMorgan	288,714	0	For
Equitable	138,793	119,220	Mixed
TIAA	254,249	0	For
American Century	163,093	0	For
BRIDGEWAY FUNDS INC	133,300	0	For
QUANTITATIVE MASTER SERIES LLC	132,546	0	For
Goldman Sachs	131,537	0	For
AIG/SunAmerica	90,747	0	For
Lincoln Financial	78,650	4,025	For
Brighthouse	70,784	0	For
MASTER INVESTMENT PORTFOLIO	70,325	0	For
Delaware/Macquarie	70,000	0	For
Nationwide	64,479	0	For
T. Rowe Price	50,656	0	For
Global X	46,292	0	For
Voya	44,486	0	For
Northern Trust	40,817	0	For
Pacific Life	39,227	0	For
Bridge Builder Trust	36,183	0	For
Invesco	34,510	0	For
Columbia Threadneedle	33,201	0	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

3. Elect Director: Polly Murphy, DVM, PhD

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%WITHHELD

FOR: 41,184,263WITHHELD: 18,015,408

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: Election of Class II Directors: Polly Murphy, DVM, PhD

ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Polly Murphy, DVM, PhD”): 41,184,263 for, 18,015,408 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 70% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 14,180,450 for, 1,075,524 withheld, 49,084 abstained.

FOR

FOR: 14,180,450ABSTAIN: 49,084WITHHOLD: 1,075,524

Largest asset managers voting on “Election of Class II Directors: Polly Murphy, DVM, PhD” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Withheld	Vote
Vanguard	4,765,568	0	For
Fidelity	3,979,498	3,489	For
BlackRock	3,647,018	0	For
Charles Schwab	621,155	0	For
JPMorgan	288,714	0	For
Equitable	138,793	119,220	Mixed
TIAA	254,249	0	For
American Century	0	163,093	Withhold
BRIDGEWAY FUNDS INC	0	133,300	Withhold
QUANTITATIVE MASTER SERIES LLC	132,546	0	For
Goldman Sachs	0	131,537	Withhold
AIG/SunAmerica	0	90,747	Withhold
Lincoln Financial	78,650	4,025	For
Brighthouse	42,429	28,355	Mixed
MASTER INVESTMENT PORTFOLIO	70,325	0	For
Delaware/Macquarie	0	70,000	Withhold
Nationwide	21,608	42,871	Mixed
T. Rowe Price	50,656	0	For
Global X	0	46,292	Withhold
Voya	0	44,486	Withhold
Northern Trust	0	40,817	Withhold
Pacific Life	39,227	0	For
Bridge Builder Trust	36,183	0	For
Invesco	0	34,510	Withhold
Columbia Threadneedle	0	33,201	Withhold

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

4. 3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 8 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST

FOR: 46,450,302AGAINST: 12,107,029

Details: description as filed, official tally, votes by 119 asset managers

Description as filed by funds: APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPANY.

ATEA PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 46,450,302 for, 12,107,029 against, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 43 asset managers voting on “APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPA” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	4,765,568	0	For
Fidelity	3,982,987	0	For
BlackRock	3,647,018	0	For
Charles Schwab	621,155	0	For
JPMorgan	0	288,714	Against
Equitable	258,013	0	For
TIAA	254,249	0	For
American Century	0	163,093	Against
BRIDGEWAY FUNDS INC	0	133,300	Against
QUANTITATIVE MASTER SERIES LLC	132,546	0	For
Goldman Sachs	131,537	0	For
AIG/SunAmerica	90,747	0	For
Lincoln Financial	61,625	21,050	Mixed
Brighthouse	28,355	42,429	Mixed
MASTER INVESTMENT PORTFOLIO	70,325	0	For
Delaware/Macquarie	70,000	0	For
Nationwide	64,479	0	For
T. Rowe Price	50,656	0	For
Global X	46,292	0	For
Voya	44,486	0	For
Northern Trust	40,817	0	For
Pacific Life	39,227	0	For
Bridge Builder Trust	36,183	0	For
Invesco	34,510	0	For
Columbia Threadneedle	33,201	0	For

Fund voting reports, all 43 managers: 14,652,211 for, 656,100 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 91 asset managers voting on “APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPA” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	6,015,477	0	For
BlackRock	3,315,373	671	For
Bain Capital Life Sciences Investors, LLC	2,485,638	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,932,350	0	For
State Street	1,406,710	3,213	For
Renaissance	1,053,679	0	For
Charles Schwab	621,303	0	For
Newtyn Management, LLC	580,000	0	For
JPMorgan	0	565,076	Against
Northern Trust	432,950	0	For
Two Sigma	423,858	0	For
Nuveen	255,847	0	For
DE Shaw	255,554	0	For
MELLON INVESTMENTS Corp	237,800	0	For
Wellington	221,694	0	For
American Century	0	163,093	Against
Dimensional	156,281	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	147,137	0	For
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0	143,100	Against
AllianceBernstein	119,220	0	For
Point72	116,734	0	For
STRS OHIO	105,500	0	For
Maryland State Retirement & Pension System	94,445	0	For
STATE OF WISCONSIN INVESTMENT BOARD	93,800	0	For
Vanguard	89,081	0	For

Institutional-manager reports, all 91 managers: 20,920,139 for, 1,033,891 against. Showing the 25 largest; see all in the interactive database.

5. 2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 73,766,274AGAINST: 1,192,659

Details: description as filed, official tally, votes by 43 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

ATEA PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025”): 73,766,274 for, 1,192,659 against, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 15,308,311 for.

FOR

FOR: 15,308,311

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCA” at ATEA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	4,765,568	For
Fidelity	3,982,987	For
BlackRock	3,647,018	For
Charles Schwab	621,155	For
JPMorgan	288,714	For
Equitable	258,013	For
TIAA	254,249	For
American Century	163,093	For
BRIDGEWAY FUNDS INC	133,300	For
QUANTITATIVE MASTER SERIES LLC	132,546	For
Goldman Sachs	131,537	For
AIG/SunAmerica	90,747	For
Lincoln Financial	82,675	For
Brighthouse	70,784	For
MASTER INVESTMENT PORTFOLIO	70,325	For
Delaware/Macquarie	70,000	For
Nationwide	64,479	For
T. Rowe Price	50,656	For
Global X	46,292	For
Voya	44,486	For
Northern Trust	40,817	For
Pacific Life	39,227	For
Bridge Builder Trust	36,183	For
Invesco	34,510	For
Columbia Threadneedle	33,201	For

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Largest ATEA PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 85,579,475 shares outstanding at the time of that meeting.

Fund voting reports: top ATEA PHARMACEUTICALS INC. shareholders by shares voted on “APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE…”, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	5.57%
2	Fidelity	4.65%
3	BlackRock	4.26%
4	Charles Schwab	0.73%
5	JPMorgan	0.34%
6	Equitable	0.30%
7	TIAA	0.30%
8	American Century	0.19%
9	BRIDGEWAY FUNDS INC	0.16%
10	QUANTITATIVE MASTER SERIES LLC	0.15%

Institutional-manager reports: top ATEA PHARMACEUTICALS INC. shareholders by shares voted on “APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE…”, 2024-2025
#	Asset manager	% of shares outstanding
1	Fidelity	7.03%
2	BlackRock	3.87%
3	Bain Capital Life Sciences Investors, LLC	2.90%
4	GEODE CAPITAL MANAGEMENT, LLC	2.26%
5	State Street	1.65%
6	Renaissance	1.23%
7	Charles Schwab	0.73%
8	Newtyn Management, LLC	0.68%
9	JPMorgan	0.66%
10	Northern Trust	0.51%

Reported ATEA PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ATEA PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BlackRock	10.45%	13F
Jean-Pierre Sommadossi	10.37%	13G
BML Investment Partners, L.P.	8.75%	13G
FMR LLC	7.73%	DEF14A
FMR (Fidelity)	7.03%	13F
JPM Partners LLC	6.85%	DEF14A
Vanguard Group	5.52%	13F
Radoff Bradley Louis	3.95%	13D
Geode Capital	2.31%	13F
State Street	2.07%	13F

Percentages above are of 85,579,475 shares outstanding, as reported by ATEA PHARMACEUTICALS INC. on its Form 10-Q dated May 9, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ATEA PHARMACEUTICALS INC.’s 10-Q dated May 9, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At ATEA PHARMACEUTICALS INC.'s shareholder meeting held June 20, 2025, in the 2024-2025 proxy season, 119 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 777 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE… — FOR was 79% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ATEA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2025.

ATEA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.